2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Profiling, Treatment Considerations, Drug Development, Supportive Care, Biological Therapies, Transplantation, Non-Biological Therapies, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Diseases, Immunology, GVHD, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, ALL, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Study Population, Human, Adult, Animal Model
PAPER

4089 Steroid refractory GI acute gvhd is associated with distinct immune cell infiltrates and gene expression profiles

Cameron McDonald-Hyman, MD, PhD, Michael C Zaiken, PhD2, Julie R Boiko, MD, PhD, MS3, Govindarajan Thangavelu, PhD4, Megan Riddle5, Valencia Williams6, Sean I. Tracy, MD, PhD7, Michael Farrar, PhD8, Booki Min, DVM, PhD9, Geoff R Hill, MD10, Victor Tkachev, PhD11, Leslie Kean, MD, PhD12, Bruce Blazar, MD, PhD13
1 University of Minnesota, Minneapolis, Minnesota, United States
2 University of Minnesota, Minneapolis, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States
4 University of Minnesota, Minneapolis, United States
5 University of Minnesota, Minneapolis, United States
6 University of Minnesota, Minneapolis, Minnesota, United States
7 University of Minnesota, Minneapolis, Minnesota, United States
8 University of Minnesota, Minneapolis, Minnesota, United States
9 Northwestern University, Chicago, Illinois, United States
10 Fred Hutchinson Cancer Center, Seattle, Washington, United States
11 Massachusetts General Hospital, Boston, Massachusetts, United States
12 Boston Children's Hospital, Boston, Massachusetts, United States
13 University of Minnesota, Minneapolis, United States

Acute graft-versus-host disease (aGVHD) remains a leading cause of early mortality after allogeneic hematopoietic stem cell transplant (alloHCT). Corticosteroids are 1st-line therapy for aGVHD, but only ~50% of patients respond. For steroid-refractory (SR) aGVHD with severe GI involvement, mortality rates can be >75%. Ruxolitinib, FDA-approved for SR aGVHD, improves 6-month survival but only to 51%.

 

A lack of mechanistic understanding of SR aGVHD pathogenesis has hampered the development of new SR aGVHD therapeutics. While donor alloreactive T-cells are central to aGVHD initiation, GI-tract biopsies from SR aGVHD patients consistently showed significant increases in myeloid cells (monocytes, macrophages, neutrophils), implicating myeloid cells in GI SR aGVHD pathogenesis. Yet, little is known about the interplay between T-cells and myeloid cells in SR aGVHD. A more comprehensive understanding of the cellular and molecular mechanisms involved with SR aGVHD pathogenesis is critical for developing new therapies.

 

To begin to identify mechanisms underpinning SR aGVHD, we utilized a murine SR aGVHD model. Lethally irradiated BALB/c mice received C57BL/6 BM (no GVHD), or BM+T-cells (aGVHD). Mice given BM+T-cells received either PBS (vehicle) or methylprednisolone (pred; 10mg/kg) from D+3-30. In 2 pooled experiments (BM only n=16; vehicle aGVHD n=19; pred aGVHD n=27), mice receiving pred survived significantly longer than vehicle treated mice, with 35% survival at D90 compared to 0% (p=0.0016). Within pred treated mice, clinical distinctions between SR and steroid sensitive (SS) mice were delineated by weight loss (weight loss vs pre-transplant: SR ≥15%, SS 10-15%) and clinical scores (point change vs pre-treatment: SR ≥+1.5, SS <1.5). Significant increases in aGVHD severity in SR vs SS mice were apparent after alloHCT (D10: weights p=0.02, scores p=0.01; D21: weights p=0.0014, scores p<0.0001). When survival of pred treated mice was stratified by clinical SS vs SR distinction, survival within the SS group was significantly longer than SR, with 62% survival in SS at D75 compared to 0% in SR (p<0.001), with a median survival in SR of 27 days.

 

To more deeply interrogate the biology of SR vs SS aGVHD, spatial transcriptomics and spatial proteomics analyses were performed in mice electively sacrificed at D21 for GI-tract tissue collection (ileum, colon; 3 pooled experiments: n=6/tissue/group: BM only, vehicle aGVHD, SR aGVHD, SS aGVHD). Both spatial-omics approaches identified an overall increase in the proportion of myeloid cells within each SR aGVHD tissue compared to SS aGVHD, replicating results in patient SR aGVHD GI-tract biopsies. Infiltrating cell quantifications in ileum and colon revealed a 3x increase in monocytes and a 1.6x increase in T-cells in SR vs. SS aGVHD. Spatial proteomics demonstrated dense clustering of monocytes and macrophages around colonic crypts in SR aGVHD mice, while SS aGVHD mice had a diffuse, less dense pattern of infiltration. Inferred interactome analysis of spatial transcriptomics (CellChat) further identified increases in interactions between macrophages and CD8 T-cells and increases in macrophage complement binding in SR aGVHD vs. SS aGVHD.

 

Spatial transcriptomics also revealed significant differences between SS and SR aGVHD mice in the transcriptional profiles of myeloid cell (monocyte, macrophage, neutrophil) and T-cell populations within the colon and ileum. Among the top 15 differentially expressed genes within both myeloid and T-cell populations, three of the most upregulated genes across all cell types in SR aGVHD mice were involved in pathways known to induce resistance to steroid receptor signaling, including fkbp5. Ongoing analyses include spatial proteomics and transcriptomics at early timepoints after steroid treatment to identify early events that contribute to SR aGVHD pathogenesis.

 

Using a SR murine aGVHD model that faithfully simulates human SR vs SS aGVHD in survival, clinical manifestations and GI tract infiltrations, we identified that when compared to SS aGVHD, SR aGVHD GI tract tissues were characterized by a pronounced myeloid skewing, distinct macrophage/monocyte tissue localizations, unique cell-cell interactions and distinct gene expression profiles. These preclinical results extend previous clinical data implicating myeloid cells in SR aGVHD pathogenesis and identify multiple potentially targetable pathways that could be used as novel therapies in SR aGVHD.
Cameron McDonald-Hyman, MD, PhD: No relevant conflicts of interest to declare.